Clinical Trial Update: Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial testing orexin antagonism for suicide risk in major depressive disorder; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Orexin receptor antagonist (unspecified)

Snippet

Sponsor: Marianne Goodman | Conditions: Suicide Risk, Major Depressive Disorder (MDD) | Phase 2 | Status: RECRUITING